Ricardo Garcia Alemany, MD
Rheumatology · Hialeah, FLNPI 1144458233
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,152 of the $23,187 with a category attached, or 78.3%. 35 manufacturers reported payments, led by Amgen at 36.1% of the total. Reporting peaked in 2019 at $8,182 and has fallen 67.9% since, to $2,623 in 2025.
Across 882 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8K
- AbbVie$3K
- Johnson & Johnson$2K
- UCB, Inc.$2K
- Novartis$2K
- Lilly USA, LLC$1K
- plus $6K from 29 others
Across 100 payments — averaging $2206.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$125K
- Eli Lilly$60K
- AbbVie$18K
- Sun Pharmaceutical Industries Inc.$18K
What the payments were for
- Consulting fees$3,60016%
- Speaking & faculty fees$1,2005%
- Travel & lodging$1861%
- Food & beverage$18,15278%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 165 | $8,368 |
| AbbVie | 121 | $2,948 |
| Johnson & Johnson(2 entities) | 131 | $1,809 |
| UCB, Inc. | 94 | $1,775 |
| Novartis | 60 | $1,553 |
| Lilly USA, LLC | 45 | $1,066 |
| GSK | 37 | $951 |
| E.r. Squibb & Sons, L.L.C. | 54 | $888 |
| Radius Health, Inc. | 37 | $750 |
| AstraZeneca(2 entities) | 36 | $641 |
| Mallinckrodt Hospital Products Inc. | 19 | $521 |
| Aurinia Pharma U.S., Inc. | 16 | $393 |
| Pfizer | 16 | $359 |
| Sanofi | 9 | $207 |
| Sanofi-aventis U.S. LLC | 7 | $111 |
| Janssen Scientific Affairs, LLC | 2 | $106 |
| Genentech USA, Inc. | 5 | $89 |
| Scilex Pharmaceuticals Inc. | 3 | $71 |
| Medexus Pharma, Inc. | 4 | $71 |
| Pacira Therapeutics, Inc. | 1 | $70 |
| Sobi, Inc | 3 | $66 |
| Fresenius Kabi USA, LLC | 2 | $57 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Hikma Pharmaceuticals USA | 2 | $43 |
| Boehringer Ingelheim | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Bristol Myers Squibb | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Tonix Medicines, Inc. | 1 | $23 |
| Alvogen Inc | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,187 in reported general payments places this provider in the 80th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 284 | $2,002,043 |
| Cimzia (2 Pack)Certolizumab Pegol | 273 | $1,689,659 |
| OrenciaAbatacept/Maltose | 318 | $1,380,295 |
| RinvoqUpadacitinib | 138 | $904,943 |
| Humira(Cf) PenAdalimumab | 101 | $741,500 |
| Taltz AutoinjectorIxekizumab | 81 | $673,903 |
| ProliaDenosumab | 357 | $619,090 |
| ActemraTocilizumab | 135 | $506,155 |
| Simponi AriaGolimumab | 58 | $425,598 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 109 | $263,061 |
| Orencia ClickjectAbatacept | 36 | $199,273 |
| Xeljanz XrTofacitinib Citrate | 33 | $189,240 |
| BenlystaBelimumab | 26 | $135,506 |
| KevzaraSarilumab | 24 | $101,321 |
| TymlosAbaloparatide | 37 | $97,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $1,775 | $1,689,659273 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $888 | $1,427,089348 claims |
| AbbVieRinvoq | $2,948 | $904,943138 claims |
| AmgenProlia, Evenity (2 Syringes) | $8,368 | $882,151466 claims |
| Johnson & JohnsonSimponi Aria, Simponi | $1,809 | $497,12970 claims |
| GSKBenlysta | $951 | $135,50626 claims |
| SanofiKevzara | $207 | $101,32124 claims |
| Radius Health, Inc.Tymlos | $750 | $97,64237 claims |
| AstraZenecaSaphnelo | $641 | $64,56213 claims |
| Medexus Pharma, Inc.Rasuvo | $71 | $14,62724 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $71 | $1,93354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Hialeah
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
- Michael WeitzMiami$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.